{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:14Z","timestamp":1791920894656,"version":"4.3.4"},"reference-count":13,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To assess the clinical benefit of rituximab for HIV-associated Castleman disease, 5 patients infected with HIV with histologic-proven Castleman disease were prospectively enrolled to receive 4 infusions of rituximab. Clinical and biologic parameters (C-reactive protein, CD19 cell count, Kaposi sarcoma\u2013associated herpesvirus [KSHV] viral load in peripheral blood mononuclear cells) were assessed before and at different time points following rituximab infusions. Two patients died very quickly after the beginning of rituximab therapy with no effect on both KSHV viral load and CD19 cell count. Three of 5 patients were considered in complete remission with no more clinical symptoms related to Castleman disease with a follow-up of 4 to 14 months. In 2 cases, clinical remission correlated with a dramatic decrease of KSHV viral load and C-reactive protein levels and a transitory but sharp decrease of CD19 cell count. In 2 responders, we observed an aggravation of Kaposi sarcoma. Our preliminary results suggest that rituximab may be effective in controlling Castleman disease in a subset of patients, although it may exacerbate concomitant Kaposi sarcoma.<\/jats:p>","DOI":"10.1182\/blood-2003-03-0951","type":"journal-article","created":{"date-parts":[[2003,7,7]],"date-time":"2003-07-07T20:23:14Z","timestamp":1057609394000},"page":"2786-2788","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":124,"title":["Rituximab therapy for HIV-associated Castleman disease"],"prefix":"10.1182","volume":"102","author":[{"given":"Anne-Genevie\u0300ve","family":"Marcelin","sequence":"first","affiliation":[{"name":"From the Department of Virology (UPRES 2387), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris; Departments of Dermatology and Hematology, Cochin Hospital, Paris; and Department of Clinical Immunology, Necker Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Aaron","sequence":"additional","affiliation":[{"name":"From the Department of Virology (UPRES 2387), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris; Departments of Dermatology and Hematology, Cochin Hospital, Paris; and Department of Clinical Immunology, Necker Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mateus","sequence":"additional","affiliation":[{"name":"From the Department of Virology (UPRES 2387), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris; Departments of Dermatology and Hematology, Cochin Hospital, Paris; and Department of Clinical Immunology, Necker Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[{"name":"From the Department of Virology (UPRES 2387), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris; Departments of Dermatology and Hematology, Cochin Hospital, Paris; and Department of Clinical Immunology, Necker Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gorin","sequence":"additional","affiliation":[{"name":"From the Department of Virology (UPRES 2387), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris; Departments of Dermatology and Hematology, Cochin Hospital, Paris; and Department of Clinical Immunology, Necker Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Viard","sequence":"additional","affiliation":[{"name":"From the Department of Virology (UPRES 2387), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris; Departments of Dermatology and Hematology, Cochin Hospital, Paris; and Department of Clinical Immunology, Necker Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"From the Department of Virology (UPRES 2387), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris; Departments of Dermatology and Hematology, Cochin Hospital, Paris; and Department of Clinical Immunology, Necker Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dupin","sequence":"additional","affiliation":[{"name":"From the Department of Virology (UPRES 2387), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris; Departments of Dermatology and Hematology, Cochin Hospital, Paris; and Department of Clinical Immunology, Necker Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219443316900_REF1","doi-asserted-by":"crossref","unstructured":"Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer. 2002;2: 373-382.","DOI":"10.1038\/nrc797"},{"key":"2020021219443316900_REF2","doi-asserted-by":"crossref","unstructured":"Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis. 1997;175: 1198-1201.","DOI":"10.1086\/593567"},{"key":"2020021219443316900_REF3","doi-asserted-by":"crossref","unstructured":"Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96: 2069-2073.","DOI":"10.1182\/blood.V96.6.2069"},{"key":"2020021219443316900_REF4","doi-asserted-by":"crossref","unstructured":"Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10: 61-67.","DOI":"10.1097\/00002030-199601000-00009"},{"key":"2020021219443316900_REF5","doi-asserted-by":"crossref","unstructured":"Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis. 2002;35: 880-882.","DOI":"10.1086\/342696"},{"key":"2020021219443316900_REF6","unstructured":"Cattelan A, Calabro M, Gasperini P, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active anti-retroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr. 2001;28: 44-49."},{"key":"2020021219443316900_REF7","unstructured":"Dupin N, Krivine A, Calvez V, Gorin I, Franck N, Escande JP. No effect of protease inhibitor on clinical and virological evolution of Castleman's disease in an HIV-1-infected patient [letter]. AIDS. 1997;11: 1400-1401."},{"key":"2020021219443316900_REF8","unstructured":"Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;21: S34-S41."},{"key":"2020021219443316900_REF9","doi-asserted-by":"crossref","unstructured":"Zietz C, Bogner JR, Goebel FD, Lohrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med. 1999;340: 1923-1924.","DOI":"10.1056\/NEJM199906173402415"},{"key":"2020021219443316900_REF10","doi-asserted-by":"crossref","unstructured":"Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasma-blastic lymphoma. Blood. 2000;95: 1406-1412.","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412"},{"key":"2020021219443316900_REF11","doi-asserted-by":"crossref","unstructured":"Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98: 3473-3475.","DOI":"10.1182\/blood.V98.12.3473"},{"key":"2020021219443316900_REF12","doi-asserted-by":"crossref","unstructured":"Lallemand F, Desire N, Rozenbaum W, Nicolas JC, Marechal V. Quantitative analysis of human herpesvirus 8 viral load using a real time PCR assay. J Clin Microbiol. 2000;38: 1404-1408.","DOI":"10.1128\/JCM.38.4.1404-1408.2000"},{"key":"2020021219443316900_REF13","doi-asserted-by":"crossref","unstructured":"Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95: 56-61.","DOI":"10.1182\/blood.V95.1.56"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/8\/2786\/1692144\/h82003002786.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/8\/2786\/1692144\/h82003002786.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:16:23Z","timestamp":1581538583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/8\/2786\/17734\/Rituximab-therapy-for-HIVassociated-Castleman"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,15]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-03-0951","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,15]]}}}